


Utility of the HEp-2000 antinuclear antibody substrate

We write with regards to the recently published consensus paper on antinuclear antibody (ANA) staining patterns by Damoiseaux *et al* which was most informative.¹ We were surprised, however, that there was no mention or discussion of the HEp-2000 substrate (ImmunoConcepts, Sacramento, California, USA) despite the acknowledgement that anti-SS-A/Ro60 is frequently missed on indirect immunofluorescence assay (IIFA).¹ The HEp-2000 substrate is a modified HEp-2 substrate that is transfected with Ro60 cDNA and hence, over-expresses this antigen.² It produces a bright nuclear/nucleolar staining pattern under IIFA when anti-SS-A/Ro60 antibodies are present (figure 1), and is one of the most commonly detected extractable nuclear antigen antibodies.³

The HEp-2000 substrate is a sensitive way to detect anti-SS-A/Ro60 antibodies that may be otherwise missed on conventional immunoassays, such as immunoblotting and the standard HEp-2 substrate.^{4,5} However, it is not a perfect screen as the HEp-2000 substrate may still miss detection of anti-SS-A/Ro60 sera^{6,7} indicating that at least a second method for anti-SS-A/Ro60 and other antibody detection is still required.⁸ For other ANA specificities, HEp-2000 performs similarly to the standard HEp-2 substrate with no significant impact on the detection of other ANA fluorescent patterns^{9,10} and in fact, improved sensitivities.⁵

It is important to maximise the chances of identifying anti-SS-A/Ro60, for the antibody, as an example, has significant implications for fertile women for the development of neonatal lupus erythematosus which may have devastating sequelae.¹¹ We therefore recommend others to consider the HEp-2000 substrate if employing the IIFA method for ANA detection.

Adrian Y S Lee ,¹ Dimitra Beroukas,² Peter J Roberts-Thomson¹

¹Clinical Immunology and Allergy, Flinders Medical Centre, Bedford Park, South Australia, Australia

²Immunology, SA Pathology, Bedford Park, South Australia, Australia




Figure 1 Typical anti-SSA/Ro60 nuclear/nucleolar staining on the HEp-2000 substrate using serum specific for anti-Ro60 at (A) 1:80 dilution and (B) 1:2560 dilution. Even with a 32-fold dilution, the staining is still quite distinct at 1:2560 (B). Insets represent enlarged versions of representative areas on the micrograph.

Correspondence to Dr Adrian Y S Lee, Clinical Immunology and Allergy, Flinders Medical Centre, Bedford Park, South Australia, Australia; adrian.lee2@sa.gov.au

Contributors AYSL drafted the manuscript. DB contributed the figure, provided intellectual content and contributed to the manuscript. PJR-T contributed to the manuscript.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Lee AYS, Beroukas D, Roberts-Thomson PJ. *Ann Rheum Dis* 2020;**79**:e67.

Received 9 April 2019

Accepted 12 April 2019

Published Online First 14 May 2019



► <http://dx.doi.org/10.1136/annrheumdis-2019-215610>

Ann Rheum Dis 2020;**79**:e67. doi:10.1136/annrheumdis-2019-215619

ORCID iD

Adrian Y S Lee <http://orcid.org/0000-0002-5179-4803>

REFERENCES

- Damoiseaux J, Andrade LEC, Carballo OG, *et al*. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International consensus on ANA patterns (ICAP) perspective. *Ann Rheum Dis* 2019;**78**:879–89.
- Keech CL, McCluskey J, Gordon TP. Transfection and overexpression of the human 60-kDa Ro/SS-A autoantigen in HEp-2 cells. *Clinical Immunology and Immunopathology* 1994;**73**:146–51.
- Wang K-Y, Yang Y-H, Chuang Y-H, *et al*. The initial manifestations and final diagnosis of patients with high and low titers of antinuclear antibodies after 6 months of follow-up. *Journal of Microbiology, Immunology and Infection* 2011;**44**:222–8.
- Fritzler MJ, Miller BJ. Detection of autoantibodies to ss-a/ro by indirect immunofluorescence using a transfected and overexpressed human 60 kd Ro autoantigen in HEp-2 cells. *J. Clin. Lab. Anal.* 1995;**9**:218–24.
- Kidd K, Cusi K, Mueller R, *et al*. Detection and identification of significant Anas in previously determined ANA negative samples. *Clin Lab* 2005;**51**:517–21.
- Bossuyt X, Frans J, Hendrickx A, *et al*. Detection of anti-SSA antibodies by indirect immunofluorescence. *Clin Chem* 2004;**50**:2361–9.
- Choi MY, Clarke AE, St.Pierre Y, *et al*. Antinuclear antibody-negative systemic lupus erythematosus in an international inception cohort. *Arthritis Care Res.* 2018.
- Hoffman IEA, Peene I, Veys EM, *et al*. Sensitivity of ANA indirect immunofluorescence testing for the detection of anti-ENA antibodies. *Arthritis Res* 2002;**4**(Suppl 1).
- Keech CL, Howarth S, Coates T, *et al*. Rapid and sensitive detection of anti-Ro (SS-A) antibodies by indirect immunofluorescence of 60kDa Ro HEp-2 transfectants. *Pathology* 1996;**28**:54–7.
- Peene I, Van Ael W, Vandenbossche M, *et al*. Sensitivity of the HEp-2000 substrate for the detection of Anti-SSA/Ro60 antibodies. *Clinical Rheumatology* 2000;**19**:291–5.
- Lee LA. Cutaneous lupus in infancy and childhood. *Lupus* 2010;**19**:1112–7.